{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:22:58Z","timestamp":1770121378876,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"iNOVA4Health","award":["UIDB\/04462\/2020 and UIDP\/04462\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020 and UIDP\/04462\/2020"]}]},{"name":"iNOVA4Health","award":["UIDB\/04462\/2020 and UIDP\/04462\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020 and UIDP\/04462\/2020"]}]},{"name":"iNOVA4Health","award":["UIDB\/04462\/2020 and UIDP\/04462\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020 and UIDP\/04462\/2020"]}]},{"name":"iNOVA4Health","award":["UIDB\/04462\/2020 and UIDP\/04462\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020 and UIDP\/04462\/2020"]}]},{"name":"iNOVA4Health","award":["UIDB\/04462\/2020 and UIDP\/04462\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020 and UIDP\/04462\/2020"]}]},{"name":"iNOVA4Health","award":["UIDB\/04462\/2020 and UIDP\/04462\/2020"],"award-info":[{"award-number":["UIDB\/04462\/2020 and UIDP\/04462\/2020"]}]},{"name":"Associated Laboratory Ls4Future","award":["LA\/P\/0087\/2020"],"award-info":[{"award-number":["LA\/P\/0087\/2020"]}]},{"name":"Associated Laboratory Ls4Future","award":["LA\/P\/0087\/2020"],"award-info":[{"award-number":["LA\/P\/0087\/2020"]}]},{"name":"Associated Laboratory Ls4Future","award":["LA\/P\/0087\/2020"],"award-info":[{"award-number":["LA\/P\/0087\/2020"]}]},{"name":"Associated Laboratory Ls4Future","award":["LA\/P\/0087\/2020"],"award-info":[{"award-number":["LA\/P\/0087\/2020"]}]},{"name":"Associated Laboratory Ls4Future","award":["LA\/P\/0087\/2020"],"award-info":[{"award-number":["LA\/P\/0087\/2020"]}]},{"name":"Associated Laboratory Ls4Future","award":["LA\/P\/0087\/2020"],"award-info":[{"award-number":["LA\/P\/0087\/2020"]}]},{"name":"Associa\u00e7\u00e3o de Endocrinologia Oncologica"},{"name":"Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil"},{"name":"iNOVA4Health - FCT","award":["UI\/BD\/154256\/2022"],"award-info":[{"award-number":["UI\/BD\/154256\/2022"]}]},{"name":"Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04541-z","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T01:43:36Z","timestamp":1770083016000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-tumour effects of combined lenvatinib and EGFR Inhibition in advanced differentiated thyroid cancer cells"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-4106","authenticated-orcid":false,"given":"Ricardo","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Pires","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmo","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeriano","family":"Leite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago Nunes","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branca Maria","family":"Cavaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"4541_CR1","doi-asserted-by":"publisher","unstructured":"I. Landa, M.E. Cabanillas, Genomic Alterations in Thyroid Cancer: Biological and Clinical Insights. Nature Reviews Endocrinology 2023 20:2 2023, 20, 93\u2013110. https:\/\/doi.org\/10.1038\/s41574-023-00920-6","DOI":"10.1038\/s41574-023-00920-6"},{"key":"4541_CR2","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"I. Landa, T. Ibrahimpasic, L. Boucai, R. Sinha, J.A. Knauf, R.H. Shah, S. Dogan, J.C. Ricarte-Filho, G.P. Krishnamoorthy, B. Xu et al., Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Invest. 126, 1052\u20131066 (2016). https:\/\/doi.org\/10.1172\/JCI85271","journal-title":"J. Clin. Invest."},{"key":"4541_CR3","doi-asserted-by":"publisher","unstructured":"Sim\u00f5es-Pereira, R. Capit\u00e3o, E. Limbert, V. Leite, Anaplastic thyroid cancer: clinical picture of the last two decades at a single oncology referral centre and novel therapeutic options. Cancers (Basel). 11 (2019). https:\/\/doi.org\/10.3390\/CANCERS11081188","DOI":"10.3390\/CANCERS11081188"},{"key":"4541_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/THY.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger et al., 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26, 1\u2013133 (2016). https:\/\/doi.org\/10.1089\/THY.2015.0020","journal-title":"Thyroid"},{"key":"4541_CR5","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/JC.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli, B. Caillou, M. Ricard, J.D. Lumbroso, De F. Vathaire et al., Long-Term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892\u20132899 (2006). https:\/\/doi.org\/10.1210\/JC.2005-2838","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4541_CR6","doi-asserted-by":"publisher","unstructured":"De S. Leo, M. Trevisan, L. Fugazzola, Recent advances in the management of anaplastic thyroid cancer. Thyroid Res. 13 (2020). https:\/\/doi.org\/10.1186\/S13044-020-00091-W","DOI":"10.1186\/S13044-020-00091-W"},{"key":"4541_CR7","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/IJC.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"J. Matsui, Y. Yamamoto, Y. Funahashi, A. Tsuruoka, T. Watanabe, T. Wakabayashi, T. Uenaka, M. Asada, E7080, a novel inhibitor that targets multiple Kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis Inhibition. Int. J. Cancer. 122, 664\u2013671 (2008). https:\/\/doi.org\/10.1002\/IJC.23131","journal-title":"Int. J. Cancer"},{"key":"4541_CR8","doi-asserted-by":"publisher","unstructured":"P. Tang, J. Sheng, X. Peng, R. Zhang, T. Xu, J. Hu, Y. Kang, B. Wu, H. Dang, Targeting NOX4 disrupts the resistance of papillary thyroid carcinoma to chemotherapeutic drugs and lenvatinib. Cell. Death Discov. 8 (2022). https:\/\/doi.org\/10.1038\/S41420-022-00994-7","DOI":"10.1038\/S41420-022-00994-7"},{"key":"4541_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","volume":"340","author":"K Okamoto","year":"2013","unstructured":"K. Okamoto, K. Kodama, K. Takase, N.H. Sugi, Y. Yamamoto, M. Iwata, A. Tsuruoka, Antitumor activities of the targeted Multi-Tyrosine kinase inhibitor lenvatinib (E7080) against RET gene Fusion-Driven tumor models. Cancer Lett. 340, 97\u2013103 (2013). https:\/\/doi.org\/10.1016\/j.canlet.2013.07.007","journal-title":"Cancer Lett."},{"key":"4541_CR10","doi-asserted-by":"publisher","unstructured":"H.Y. Khan, J. Ge, M. Nagasaka, A. Aboukameel, G. Mpilla, I. Muqbil, M. Szlaczky, M. Chaker, E. Baloglu, Y. Landesman et al., Targeting XPO1 and PAK4 in 8505\u00a0C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. Int. J. Mol. Sci. 21 (2020). https:\/\/doi.org\/10.3390\/IJMS21010237","DOI":"10.3390\/IJMS21010237"},{"key":"4541_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMOA1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff et al., Lenvatinib versus placebo in Radioiodine-Refractory thyroid cancer. N. Engl. J. Med. 372, 621\u2013630 (2015). https:\/\/doi.org\/10.1056\/NEJMOA1406470","journal-title":"N. Engl. J. Med."},{"key":"4541_CR12","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6507.23.03982-9","author":"IL DAM\u00c1SIO","year":"2024","unstructured":"I.L. Dam\u00e1sio, A. Figueiredo, J. Maciel, M. Horta, T.N. Silva, J. SIm\u00f5es-Pereira, S. Donato, V. Leite, Effectiveness and safety of lenvatinib in a series of advanced Well-Differentiated thyroid carcinomas from a single tertiary cancer center and literature review. Minerva Endocrinol. (2024). https:\/\/doi.org\/10.23736\/S2724-6507.23.03982-9","journal-title":"Minerva Endocrinol."},{"key":"4541_CR13","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6507.25.04309-X","author":"C REGALA","year":"2025","unstructured":"C. Regala, T.N. Silva, V. Leite, The role of lenvatinib in different types of thyroid cancer. Minerva Endocrinol. (2025). https:\/\/doi.org\/10.23736\/S2724-6507.25.04309-X","journal-title":"Minerva Endocrinol."},{"key":"4541_CR14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/S41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"H. Jin, Y. Shi, Y. Lv, S. Yuan, C.F.A. Ramirez, C. Lieftink, L. Wang, S. Wang, C. Wang, M.H. Dias et al., EGFR activation limits the response of liver cancer to lenvatinib. Nature. 595, 730\u2013734 (2021). https:\/\/doi.org\/10.1038\/S41586-021-03741-7","journal-title":"Nature"},{"key":"4541_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/THY.2007.0120","volume":"18","author":"NA Pennell","year":"2008","unstructured":"N.A. Pennell, G.H. Daniels, R.I. Haddad, D.S. Ross, T. Evans, L.J. Wirth, P.H. Fidias, J.S. Temel, S. Gurubhagavatula, R.S. Heist et al., A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 18, 317\u2013323 (2008). https:\/\/doi.org\/10.1089\/THY.2007.0120","journal-title":"Thyroid"},{"key":"4541_CR16","doi-asserted-by":"publisher","first-page":"6763","DOI":"10.3892\/OL.2018.8093","volume":"15","author":"Y Jia","year":"2018","unstructured":"Y. Jia, C. Zhang, C. Hu, Y. Yu, X. Zheng, Y. Li, M..Gao EGFR Inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines. Oncol. Lett. 15, 6763\u20136769 (2018). https:\/\/doi.org\/10.3892\/OL.2018.8093","journal-title":"Oncol. Lett."},{"key":"4541_CR17","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-18-2953","volume":"25","author":"I Landa","year":"2019","unstructured":"I. Landa, N. Pozdeyev, C. Korch, L.A. Marlow, R.C. Smallridge, J.A. Copland, Y.C. Henderson, S.Y. Lai, G.L. Clayman, N. Onoda et al., Comprehensive genetic characterization of human thyroid cancer cell lines: A validated panel for preclinical studies. Clin. Cancer Res. 25, 3141\u20133151 (2019). https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2953","journal-title":"Clin. Cancer Res."},{"key":"4541_CR18","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/NAR\/GKAA216","volume":"48","author":"A Ianevski","year":"2021","unstructured":"A. Ianevski, A.K. Giri, T. Aittokallio, SynergyFinder 2.0: visual analytics of Multi-Drug combination synergies. Nucleic Acids Res. 48, W488\u2013W493 (2021). https:\/\/doi.org\/10.1093\/NAR\/GKAA216","journal-title":"Nucleic Acids Res."},{"key":"4541_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/GCC.2870100403;WGROUP:STRING:PUBLICATION","volume":"10","author":"O-P Kallioniemi","year":"1994","unstructured":"O.-P. Kallioniemi, A. Kallioniemi, J. Piper, J. Isola, F.M. Waldman, J.W. Gray, D. Pinkel, Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer. 10, 231\u2013243 (1994). https:\/\/doi.org\/10.1002\/GCC.2870100403;WGROUP:STRING:PUBLICATION","journal-title":"Genes Chromosomes Cancer"},{"key":"4541_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"N Agrawal","year":"2014","unstructured":"N. Agrawal, R. Akbani, B.A. Aksoy, A. Ally, H. Arachchi, S.L. Asa, J.T. Auman, M. Balasundaram, S. Balu, S.B. Baylin et al., Integr. Genomic Charact. Papillary Thyroid Carcinoma Cell. 159, 676\u2013690 (2014). https:\/\/doi.org\/10.1016\/j.cell.2014.09.050","journal-title":"Integr. Genomic Charact. Papillary Thyroid Carcinoma Cell"},{"key":"4541_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/THY.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"K.C. Bible, E. Kebebew, J. Brierley, J.P. Brito, M.E. Cabanillas, T.J. Clark, Di A. Cristofano, R. Foote, T. Giordano, J. Kasperbauer et al., 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 31, 337\u2013386 (2021). https:\/\/doi.org\/10.1089\/THY.2020.0944","journal-title":"Thyroid"},{"key":"4541_CR22","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1158\/0008-5472.CAN-21-4140","volume":"82","author":"B Hu","year":"2022","unstructured":"B. Hu, T. Zou, W. Qin, X. Shen, Y. Su, J. Li, Y. Chen, Z. Zhang, H. Sun, Y. Zheng et al., Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3\u2013ABCB1 signaling in hepatocellular carcinoma. Cancer Res. 82, 3845\u20133857 (2022). https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-4140","journal-title":"Cancer Res."},{"key":"4541_CR23","doi-asserted-by":"publisher","first-page":"R173","DOI":"10.1530\/ERC-22-0129","volume":"29","author":"MC Hofmann","year":"2022","unstructured":"M.C. Hofmann, M. Kunnimalaiyaan, J.R. Wang, N.L. Busaidy, S.I. Sherman, S.Y. Lai, M. Zafereo, M.E. Cabanillas, Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers. Endocr. Relat. Cancer. 29, R173\u2013R190 (2022). https:\/\/doi.org\/10.1530\/ERC-22-0129","journal-title":"Endocr. Relat. Cancer"},{"key":"4541_CR24","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1111\/CAS.15465","volume":"113","author":"K Ohno","year":"2022","unstructured":"K. Ohno, T. Shibata, K. Ito, Ichi Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells. Cancer Sci. 113, 3193\u20133210 (2022). https:\/\/doi.org\/10.1111\/CAS.15465","journal-title":"Cancer Sci."},{"key":"4541_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.lungcan.2019.09.011","volume":"138","author":"T Hida","year":"2019","unstructured":"T. Hida, V. Velcheti, K.L. Reckamp, H. Nokihara, P. Sachdev, T. Kubota, T. Nakada, C.E. Dutcus, M. Ren, T.A. Tamura, Phase 2 study of lenvatinib in patients with RET Fusion-Positive lung adenocarcinoma. Lung Cancer. 138, 124\u2013130 (2019). https:\/\/doi.org\/10.1016\/j.lungcan.2019.09.011","journal-title":"Lung Cancer"},{"key":"4541_CR26","doi-asserted-by":"publisher","unstructured":"O. Tohyama, J. Matsui, K. Kodama, N. Hata-Sugi, T. Kimura, K. Okamoto, Y. Minoshima, M. Iwata, Y. Funahashi, Antitumor activity of lenvatinib (E7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J. Thyroid Res. 2014 (2014). https:\/\/doi.org\/10.1155\/2014\/638747","DOI":"10.1155\/2014\/638747"},{"key":"4541_CR27","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1158\/0008-5472.CAN-08-0413","volume":"68","author":"M Croyle","year":"2008","unstructured":"M. Croyle, N. Akeno, J.A. Knauf, D. Fabbro, X. Chen, J.E. Baumgartner, H.A. Lane, J.A. Fagin, RET\/PTC-Induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res. 68, 4183\u20134191 (2008). https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0413","journal-title":"Cancer Res."},{"key":"4541_CR28","doi-asserted-by":"publisher","unstructured":"J.M. Pita, E. Rasp\u00e9, K. Coulonval, M. Decaussin-Petrucci, M. Tarabichi, G. Dom, F. Libert, L. Craciun, G. Andry, L. Wicquart et al., CDK4 phosphorylation status and rational use for combining CDK4\/6 and BRAF\/MEK Inhibition in advanced thyroid carcinomas. Front. Endocrinol. (Lausanne). 14 (2023). https:\/\/doi.org\/10.3389\/FENDO.2023.1247542","DOI":"10.3389\/FENDO.2023.1247542"},{"key":"4541_CR29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.20517\/CDR.2019.10","volume":"2","author":"X Wang","year":"2019","unstructured":"X. Wang, H. Zhang, X. Chen, Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2, 141\u2013160 (2019). https:\/\/doi.org\/10.20517\/CDR.2019.10","journal-title":"Cancer Drug Resist."},{"key":"4541_CR30","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1158\/1535-7163.MCT-15-0088","volume":"14","author":"BW Murray","year":"2015","unstructured":"B.W. Murray, N. Miller, Durability of Kinase-Directed Therapies - A network perspective on response and resistance. Mol. Cancer Ther. 14, 1975\u20131984 (2015). https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0088","journal-title":"Mol. Cancer Ther."},{"key":"4541_CR31","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2147\/DDDT.S93459","volume":"10","author":"R Costa","year":"2016","unstructured":"R. Costa, B.A. Carneiro, S. Chandra, S.G. Pai, Y.K. Chae, J.B. Kaplan, H.B. Garrett, M. Agulnik, P.A. Kopp, F.J. Giles, Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des. Devel Ther. 10, 873\u2013884 (2016). https:\/\/doi.org\/10.2147\/DDDT.S93459","journal-title":"Drug Des. Devel Ther."},{"key":"4541_CR32","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1158\/1535-7163.MCT-16-0196","volume":"15","author":"JJ Wheler","year":"2016","unstructured":"J.J. Wheler, F. Janku, A. Naing, Y. Li, B. Stephen, R. Zinner, V. Subbiah, S. Fu, D. Karp, G.S. Falchook et al., TP53 alterations correlate with response to VEGF\/VEGFR inhibitors: implications for targeted therapeutics. Mol. Cancer Ther. 15, 2475\u20132485 (2016). https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0196","journal-title":"Mol. Cancer Ther."},{"key":"4541_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/S13691-022-00573-8","volume":"12","author":"A Tsukaguchi","year":"2022","unstructured":"A. Tsukaguchi, S. Ihara, H. Yasuoka, S. Minami, Lenvatinib-Refractory thymic mucinous carcinoma with PIK3CA mutation. Int. Cancer Conf. J. 12, 36\u201340 (2022). https:\/\/doi.org\/10.1007\/S13691-022-00573-8","journal-title":"Int. Cancer Conf. J."},{"key":"4541_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/NRENDO.2011.142","volume":"7","author":"YE Nikiforov","year":"2011","unstructured":"Y.E. Nikiforov, M.N. Nikiforova, Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol. 7, 569\u2013580 (2011). https:\/\/doi.org\/10.1038\/NRENDO.2011.142","journal-title":"Nat. Rev. Endocrinol."},{"key":"4541_CR35","doi-asserted-by":"publisher","unstructured":"T. Randic, I. Kozar, C. Margue, J. Utikal, S.. Kreis, NRAS Mutant melanoma: towards better therapies. Cancer Treat. Rev. 99 (2021). https:\/\/doi.org\/10.1016\/j.ctrv.2021.102238","DOI":"10.1016\/j.ctrv.2021.102238"},{"key":"4541_CR36","doi-asserted-by":"publisher","unstructured":"L. Jiang, L. Li, Y. Liu, L. Lu, M. Zhan, S. Yuan, Y. Liu, Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma. Front. Pharmacol. 14 (2023). https:\/\/doi.org\/10.3389\/FPHAR.2023.1097277","DOI":"10.3389\/FPHAR.2023.1097277"},{"key":"4541_CR37","doi-asserted-by":"publisher","unstructured":"G. Liu, T. Chen, Z. Ding, Y. Wang, Y. Wei, X. Wei, Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Cell. Prolif. 54 (2021). https:\/\/doi.org\/10.1111\/CPR.13009","DOI":"10.1111\/CPR.13009"},{"key":"4541_CR38","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2174\/1568009622666220428111327","volume":"22","author":"J Guo","year":"2022","unstructured":"J. Guo, J. Zhao, Q. Xu, D. Huang, Resistance of lenvatinib in hepatocellular carcinoma. Curr. Cancer Drug Targets. 22, 865\u2013878 (2022). https:\/\/doi.org\/10.2174\/1568009622666220428111327","journal-title":"Curr. Cancer Drug Targets"},{"key":"4541_CR39","doi-asserted-by":"publisher","unstructured":"K. Shi, G. Wang, J. Pei, J. Zhang, J. Wang, L. Ouyang, Y. Wang, W. Li, Emerging strategies to overcome resistance to Third-Generation EGFR inhibitors. J. Hematol. Oncol. 15 (2022). https:\/\/doi.org\/10.1186\/S13045-022-01311-6","DOI":"10.1186\/S13045-022-01311-6"},{"key":"4541_CR40","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1097\/JTO.0000000000000688","volume":"10","author":"TM Kim","year":"2015","unstructured":"T.M. Kim, A. Song, D.W. Kim, S. Kim, Y.O. Ahn, B. Keam, Y.K. Jeon, S.H. Lee, D.H. Chung, D.S. Heo, Mechanisms of acquired resistance to AZD9291: A Mutation-Selective, irreversible EGFR inhibitor. J. Thorac. Oncol. 10, 1736\u20131744 (2015). https:\/\/doi.org\/10.1097\/JTO.0000000000000688","journal-title":"J. Thorac. Oncol."},{"key":"4541_CR41","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/S41568-023-00598-Y","volume":"23","author":"JA Fagin","year":"2023","unstructured":"J.A. Fagin, G.P. Krishnamoorthy, I. Landa, Pathogenesis of cancers derived from thyroid follicular cells. Nat. Rev. Cancer. 23, 631\u2013650 (2023). https:\/\/doi.org\/10.1038\/S41568-023-00598-Y","journal-title":"Nat. Rev. Cancer"},{"key":"4541_CR42","doi-asserted-by":"publisher","unstructured":"Y. Tian, W.A. Guo, Review of the molecular pathways involved in resistance to BRAF inhibitors in patients with Advanced-Stage melanoma. Med. Sci. Monit. 26 (2020). https:\/\/doi.org\/10.12659\/MSM.920957","DOI":"10.12659\/MSM.920957"},{"key":"4541_CR43","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.2147\/OTT.S220462","volume":"12","author":"D Zhang","year":"2019","unstructured":"D. Zhang, L.L. Han, F. Du, X.M. Liu, J. Li, H.H. Wang, M.H. Song, Z. Li, G.Y. Li, FGFR1 induces acquired resistance against gefitinib by activating AKT\/MTOR pathway in NSCLC. Onco Targets Ther. 12, 9809\u20139816 (2019). https:\/\/doi.org\/10.2147\/OTT.S220462","journal-title":"Onco Targets Ther."},{"key":"4541_CR44","doi-asserted-by":"publisher","unstructured":"K.E. Ware, T.K. Hinz, E. Kleczko, K.R. Singleton, L.A. Marek, B.A. Helfrich, C.T. Cummings, D.K. Graham, D. Astling, A.C. Tan et al., A Mechanism of Resistance to Gefitinib Mediated by Cellular Reprogramming and the Acquisition of an FGF2-FGFR1 Autocrine Growth Loop. Oncogenesis 2013, 2, https:\/\/doi.org\/10.1038\/ONCSIS.2013.4","DOI":"10.1038\/ONCSIS.2013.4"},{"key":"4541_CR45","doi-asserted-by":"publisher","unstructured":"R. Raman, J.A. Villefranc, T.M. Ullmann, J. Thiesmeyer, V. Anelli, J. Yao, J.R. Hurley, C. Pauli, R. Bareja, K.W. Eng et al., Inhibition of FGF receptor blocks adaptive resistance to RET Inhibition in CCDC6-RET\u2013Rearranged thyroid cancer. J. Exp. Med. 219 (2022). https:\/\/doi.org\/10.1084\/JEM.20210390","DOI":"10.1084\/JEM.20210390"},{"key":"4541_CR46","doi-asserted-by":"publisher","unstructured":"F.M. Fan, J.S. Fleishman, J. Chen, Z.S. Chen, H.H. Dong, New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma. Drug Discov Today. 29 (2024). https:\/\/doi.org\/10.1016\/j.drudis.2024.104069","DOI":"10.1016\/j.drudis.2024.104069"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04541-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04541-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04541-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T01:43:37Z","timestamp":1770083017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04541-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4541"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04541-z","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"59"}}